Organoids are self-organizing 3D cultures derived from stem cells that recapitulate aspects of organ architecture and function. Over the past decade, they’ve transformed disease modeling, drug screening, and personalized medicine.
Where organoids come from
Two main sources:
- Adult stem cells (ASCs): Tissue-resident stem cells (e.g., LGR5+ in intestine) grown in defined media that maintains stemness while allowing differentiation. Used for intestine, stomach, liver, pancreas, prostate, breast, and many others.
- Pluripotent stem cells (iPSCs/ESCs): Differentiated through staged signaling protocols. Used for brain, retina, kidney, and other organs that can’t easily be sourced as primary tissue.
Major applications
Cancer modeling
Patient-derived tumor organoids (PDOs) maintain genetic, epigenetic, and phenotypic heterogeneity of the original tumor better than cell lines. Used for:
- Drug sensitivity profiling for personalized treatment selection
- Studying clonal evolution under therapeutic pressure
- Co-culture with autologous immune cells for immunotherapy modeling
Infectious disease
Organoids host pathogens that resist propagation in 2D culture. Examples include human norovirus (intestinal organoids), Helicobacter pylori (gastric), SARS-CoV-2 (lung and intestinal), and Cryptosporidium.
Inherited disease
iPSC-derived organoids carrying patient mutations recapitulate disease phenotypes. Used for cystic fibrosis (CFTR function in intestinal organoids), polycystic kidney disease, and neurodevelopmental disorders.
Developmental biology
Brain organoids reveal stages of cortical development. Retinal organoids form layered structures with photoreceptors. Kidney organoids form nephron-like structures.
Drug discovery
Toxicity testing (especially hepatotoxicity in liver organoids), efficacy screening, and ADME prediction. Organoids generally predict in vivo response better than 2D models.
Limitations to be aware of
- Lack of vasculature. Most organoids are avascular, limiting size and creating necrotic cores in larger structures
- Lack of immune components. Standard organoids don’t include immune cells; co-culture or assembloids can address this
- Variable architecture. Self-organization varies between batches and experiments — reproducibility is harder than 2D
- Maturity. iPSC-derived organoids often resemble fetal rather than adult tissue
- Cost and time. Organoid culture is more expensive and labor-intensive than 2D
Recent innovations
- Assembloids: Fusing multiple organoid types (e.g., cortical + thalamic) to model inter-region connectivity
- Vascularization: Co-culture with endothelial cells or in vivo transplantation
- Bioprinted organoids: Defined geometry and reproducibility
- Microfluidic “organ-on-chip”: Combining organoids with controlled flow and mechanical cues
- CRISPR-engineered organoids: Introducing or correcting disease mutations in patient lines
Practical considerations for new users
- Choose ASC-derived organoids for tissues with accessible primary stem cells; iPSC-derived for tissues that aren’t
- Use defined media (StemCell Technologies, Hubrecht protocols) for consistency
- Document organoid morphology and growth kinetics — phenotypes drift over passages
- Build in scRNA-seq or marker-based QC at intervals to catch drift
- For drug screening, normalize for organoid size and starting cell number
Organoids aren’t a replacement for animal models or clinical trials — but they’re often the most translationally relevant model available without going in vivo. Use them where heterogeneity, architecture, and human-specific biology matter.
